Update on the management of inflammatory bowel disease: specific role of adalimumab

Anti-tumor necrosis factor alpha (TNF-α) medications are a class of biologics employed in the treatment of patients with inflammatory bowel disease (IBD). Adalimumab is the first fully human monoclonal immunoglobulin directed against TNF-α, which binds with high affinity and specificity to membrane...

Descripción completa

Detalles Bibliográficos
Autores principales: Guidi, Luisa, Pugliese, Daniela, Armuzzi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163921/
https://www.ncbi.nlm.nih.gov/pubmed/21904462
http://dx.doi.org/10.2147/CEG.S14558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163921/
https://www.ncbi.nlm.nih.gov/pubmed/21904462
http://dx.doi.org/10.2147/CEG.S14558

Ejemplares similares